Lorrie Schifano

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

Valerie J. Ludbrook, Kirsty Hicks, Kate Hanrott et al. · British Journal of Dermatology · 2016 · 80 citations

Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus

Lesley Kahl, Jessal J. Patel, Mark Layton et al. · Lupus · 2016 · 66 citations

Immunodeficiencies, Immunology, Pharmacotherapy +18

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

Jatin Patel, Damon Bass, Albertus Beishuizen et al. · European Respiratory Journal · 2022 · 42 citations · Full text

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

Roy Fleischmann, Désirée van der Heijde, Vibeke Strand et al. · Annals of the Rheumatic Diseases · 2023 · 29 citations · Full text

A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR)

Jatin Patel, Albertus Beishuizen, Xavier Bocca Ruiz et al. · 2021 · 27 citations · Full text

Acute Lung Injury, Immunology, Logistic Analysis +18